Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome - PubMed (original) (raw)
. 2002 Dec;161(6):1991-6.
doi: 10.1016/S0002-9440(10)64476-8.
Charles M Perou, Rob Tibshirani, Phillippe Haas, Olli Kallioniemi, Juha Kononen, Joachim Torhorst, Guido Sauter, Markus Zuber, Ossi R Köchli, Frank Mross, Holger Dieterich, Rob Seitz, Doug Ross, David Botstein, Pat Brown
Affiliations
- PMID: 12466114
- PMCID: PMC1850928
- DOI: 10.1016/S0002-9440(10)64476-8
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome
Matt van de Rijn et al. Am J Pathol. 2002 Dec.
Erratum in
- Am J Pathol. 2003 Jul;163(1):377
Abstract
While several prognostic factors have been identified in breast carcinoma, the clinical outcome remains hard to predict for individual patients. Better predictive markers are needed to help guide difficult treatment decisions. In a previous study of 78 breast carcinoma specimens, we noted an association between poor clinical outcome and the expression of cytokeratin 17 and/or cytokeratin 5 mRNAs. Here we describe the results of immunohistochemistry studies using monoclonal antibodies against these markers to analyze more than 600 paraffin-embedded breast tumors in tissue microarrays. We found that expression of cytokeratin 17 and/or cytokeratin 5/6 in tumor cells was associated with a poor clinical outcome. Moreover, multivariate analysis showed that in node-negative breast carcinoma, expression of these cytokeratins was a prognostic factor independent of tumor size and tumor grade.
Figures
Figure 1.
A: Normal mammary gland simultaneously stained with CAM5.2 monoclonal antibody [specific for keratins 8 and 18] (blue), and monoclonal anti-cytokeratin 17 (brown). Note that the CAM5.2 antibody specifically stains the lumenal epithelial cells, while the anti-cytokeratin 17 antibody specifically stains the basal epithelial cells of the normal mammary duct. B: Whole paraffin section of breast carcinoma stained with CAM5.2 monoclonal antibody (blue), and monoclonal anti-cytokeratin 17 (brown). Note the focal staining pattern for cytokeratin 17.
Figure 2.
A: Kaplan-Meier survival curve showing poor outcome in cytokeratin 17- and/or 5/6-positive tumors (P = 0.012). Clinical follow-up was available for 505 patients (mean, 65.9 months). A: No expression of CK17 or cytokeratin 5/6 in tumor cells. B: Expression of CK17 and/or cytokeratin 5/6 in tumor cells. B: The effect of cytokeratin 17 and/or cytokeratin 5/6 expression in 245 patients with negative lymph nodes (P = 0.006). The lymph node status was known in 474 patients. Patients expressing basal keratin (B) in this group have worse outcome than in patients without expression of these markers (A). Multivariate analysis showed that this effect was independent of tumor size, tumor grade, or Her2neu, ER, or GATA-3 expression.
Similar articles
- Expression of luminal and basal cytokeratins in human breast carcinoma.
Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI, Ellis IO. Abd El-Rehim DM, et al. J Pathol. 2004 Jun;203(2):661-71. doi: 10.1002/path.1559. J Pathol. 2004. PMID: 15141381 - [Relationship between the expression of matrix metalloproteinase-13 protein and other biomarkers, prognosis in invasive breast cancer].
Zhang B, Liu YX, Cao WF, Cao XC, Ning LS, Hao XS. Zhang B, et al. Zhonghua Bing Li Xue Za Zhi. 2008 Jul;37(7):471-6. Zhonghua Bing Li Xue Za Zhi. 2008. PMID: 19035119 Chinese. - Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.
Rodríguez-Pinilla SM, Sarrió D, Honrado E, Hardisson D, Calero F, Benitez J, Palacios J. Rodríguez-Pinilla SM, et al. Clin Cancer Res. 2006 Mar 1;12(5):1533-9. doi: 10.1158/1078-0432.CCR-05-2281. Clin Cancer Res. 2006. PMID: 16533778 - Mucins and Cytokeratins as Serum Tumor Markers in Breast Cancer.
Nicolini A, Ferrari P, Rossi G. Nicolini A, et al. Adv Exp Med Biol. 2015;867:197-225. doi: 10.1007/978-94-017-7215-0_13. Adv Exp Med Biol. 2015. PMID: 26530368 Review. - Cytokeratin markers come of age.
Linder S. Linder S. Tumour Biol. 2007;28(4):189-95. doi: 10.1159/000107582. Epub 2007 Aug 23. Tumour Biol. 2007. PMID: 17717426 Review.
Cited by
- Bi-level Graph Learning Unveils Prognosis-Relevant Tumor Microenvironment Patterns in Breast Multiplexed Digital Pathology.
Wang Z, Santa-Maria CA, Popel AS, Sulam J. Wang Z, et al. bioRxiv [Preprint]. 2024 Oct 4:2024.04.22.590118. doi: 10.1101/2024.04.22.590118. bioRxiv. 2024. PMID: 38712207 Free PMC article. Preprint. - The role of URO17® in diagnosis and follow up of bladder cancer patients.
Ibrahim M, Rabinowitz J, Hilbert R, Ghose A, Agarwal S, Swamy R, Bulut I, Guttierrez M, Buali E, Nassar E, Jhavar P, Al-Hashimi F, Vasdev N. Ibrahim M, et al. BMC Urol. 2024 Feb 9;24(1):34. doi: 10.1186/s12894-024-01426-7. BMC Urol. 2024. PMID: 38336681 Free PMC article. - Expression of the Immunohistochemical Markers CK5, CD117, and EGFR in Molecular Subtypes of Breast Cancer Correlated with Prognosis.
Schulmeyer CE, Fasching PA, Häberle L, Meyer J, Schneider M, Wachter D, Ruebner M, Pöschke P, Beckmann MW, Hartmann A, Erber R, Gass P. Schulmeyer CE, et al. Diagnostics (Basel). 2023 Jan 19;13(3):372. doi: 10.3390/diagnostics13030372. Diagnostics (Basel). 2023. PMID: 36766486 Free PMC article. - Molecular and pathological subtypes related to prostate cancer disparities and disease outcomes in African American and European American patients.
Mori JO, White J, Elhussin I, Duduyemi BM, Karanam B, Yates C, Wang H. Mori JO, et al. Front Oncol. 2022 Aug 10;12:928357. doi: 10.3389/fonc.2022.928357. eCollection 2022. Front Oncol. 2022. PMID: 36033462 Free PMC article. - Exploitation of High Tumour GSH Levels for Targeted siRNA Delivery in Rhabdomyosarcoma Cells.
Duan C, Townley H. Duan C, et al. Biomolecules. 2022 Aug 17;12(8):1129. doi: 10.3390/biom12081129. Biomolecules. 2022. PMID: 36009022 Free PMC article.
References
- Henson DE, Fielding LP, Grignon DJ, Page DL, Hammond ME, Nash G, Pettigrew NM, Gorstein F, Hutter RV: College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors: Summary Members of the Cancer Committee. Arch Pathol Lab Med 1995, 119:1109-1112 - PubMed
- Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998, 11:155-168 - PubMed
- Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang C, Kobayashi M, Horton H, Brown EL: Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996, 14:1675-1680 - PubMed
- Chee M, Yang R, Hubbell E, Berno A, Huang XC, Stern D, Winkler J, Lockhart DJ, Morris MS, Fodor SP: Accessing genetic information with high-density DNA arrays. Science 1996, 274:610-614 - PubMed
- Cheung VG, Morley M, Aguilar F, Massimi A, Kucherlapati R, Childs G: Making and reading microarrays. Nat Genet 1999, 21:15-19 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous